Normalization of the tumor marker CA-125 after oophorectomy in a patient with paraneoplastic cerebellar degeneration without detectable cancer

Gynecologic Oncology

Volumn 65, Issue 1, 1997, Pages 173-176

  Mason, Warren P ^a   Dalmau, Josep ^a   Curtin, John P ^a   Posner, Jerome B ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINUCLEAR ANTIBODY; CA 125 ANTIGEN; TUMOR MARKER;

ADULT; ARTICLE; CASE REPORT; CEREBELLUM DEGENERATION; FEMALE; HUMAN; LEUKOCYTOSIS; OCCULT CANCER; OVARIECTOMY; PARANEOPLASTIC SYNDROME; PRIORITY JOURNAL; SALPINGOOOPHORECTOMY;

EID: 0031127627     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1006/gyno.1997.4618     Document Type: Article

References (14)

1. 1. Posner JB: Paraneoplastic cerebellar degeneration. Can J Neurol Sci 20:S117-S122, 1993
2. 2. Greenlee JE, Brashear HR: Antibodies to cerebellar Purkinje cells in patients with paraneoplastic cerebellar degeneration and ovarian cancer. Ann Neurol 14:609-613, 1983
3. 3. Peterson K, Rosenblum MK, Kotanides H, Posner JB: Paraneoplastic cerebellar degeneration: A clinical analysis of 55 anti-Yo antibody-positive patients. Neurology 42:1931-1937, 1992
4. 4. Dalmau J, Graus F, Rosenblum MK, Posner JB: Anti-Hu-associated paraneoplastic encephalomyelitis/sensory neuronopathy: A clinical study of 71 patients. Medicine 71:59-72, 1992
5. 5. Anderson NE, Budde-Steffen C, Wiley RG, et al: A variant of the anti-Purkinje cell antibody in a patient with paraneoplastic cerebellar degeneration. Neurology 38:1018-1026, 1988
6. 6. Darnell RB, DeAngelis LM: Regression of small cell lung carcinoma in patients with paraneoplastic neuronal antibodies. Lancet 341:21-22, 1993
7. 7. Kammerer-Doak DN, Magrina JF, Nemiro JS, Lidner TK: Benign gynecologic conditions associated with a CA-125 level >1,000 U/ml. J Reprod Med 41:179-182, 1996
8. 8. Apel RL, Fernandes BJ: Malignant lymphoma presenting with an elevated serum CA-125 level. Arch Pathol Lab Med 119:373-376, 1995
9. 9. Bast RC, Klug TL, John ES, et al: A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N Engl J Med 309:883-887, 1983
10. 10. Canney PA, Moore M, Wilkinson PM, James RD: Ovarian cancer antigen CA 125: A prospective clinical assessment of its role as a tumour marker. Br J Cancer 50:765-769, 1984
11. 11. Rustin GJS, Nelstrop AE, McClean P, et al: Defining response of ovarian carcinoma to initial chemotherapy according to serum CA 125. J Clin Oncol 14:1545-1551, 1996
12. 12. Posner JB, Dalmau J: Neurological paraneoplastic syndromes: A review of diagnosis and prospects for therapy. J Clin Neurosci 3:8-15, 1996
13. 13. Henson RA, Urich H: Cortical Cerebellar Degeneration, in Henson RA, Urich H (eds): Cancer and the Nervous System. Oxford, Blackwell Sci, 1982, pp 314-345
14. 14. Twijnstra A, Verschuuren J, Byrne TN, De Baets M, Posner JB, Dalmau J: Prolonged or remitting anti-Hu associated paraneoplastic sensory neuronopathy (PSN) and encephalomyelitis (PEM). Neurology 45(Suppl 4):A321, 1995